炎症性肠病药物治疗中带状疱疹的总体风险与比较风险:一项全国性队列研究
两项回顾性退伍军人队列研究(2000年1月至2016年6月)显示,溃疡性结肠炎和克罗恩病均与带状疱疹风险显著增加相关,调整后风险比分别为1.81和1.56;与单用5-氨基水杨酸相比,硫嘌呤类或硫嘌呤联合TNF拮抗剂增加带状疱疹风险,而单用TNF拮抗剂未显著增加风险。
要点
- 溃疡性结肠炎和克罗恩病患者的带状疱疹风险均显著高于无炎症性肠病人群。
- 与单用5-氨基水杨酸相比,硫嘌呤类或硫嘌呤联合TNF拮抗剂增加带状疱疹风险。
- 单用TNF拮抗剂未显著增加带状疱疹风险。
核心结论
- 在两项回顾性退伍军人队列研究中,炎症性肠病以及使用硫嘌呤类(单用或联合TNF拮抗剂)与带状疱疹风险增加相关。
- 作者认为,随着新的可能更安全的带状疱疹疫苗获批,应研究炎症性肠病患者免疫接种的效果。
研究设计与样本
- 两项回顾性研究,人群为退伍军人,时间范围为2000年1月至2016年6月。
- 研究1比较单用5-氨基水杨酸治疗的炎症性肠病患者与匹配的无炎症性肠病人群的带状疱疹发病率。
- 研究2比较单用5-氨基水杨酸、硫嘌呤类、TNF拮抗剂、硫嘌呤联合TNF拮抗剂以及维多珠单抗治疗的炎症性肠病患者的带状疱疹发病率。
- 采用多变量Cox回归估计风险比和95%CI,并按年龄和炎症性肠病药物亚组估计带状疱疹发病率。
主要发现
- 与无炎症性肠病相比,溃疡性结肠炎和克罗恩病均与带状疱疹感染风险显著增加相关。
- 多变量Cox回归中,与无炎症性肠病相比,溃疡性结肠炎的调整后风险比为1.81(95%CI,1.56-2.11),克罗恩病为1.56(95%CI,1.28-1.91),单用5-氨基水杨酸治疗的炎症性肠病为1.72(95%CI,1.51-1.96)。
- 与单用5-氨基水杨酸相比,硫嘌呤类的调整后风险比为1.47(95%CI,1.31-1.65),硫嘌呤联合TNF拮抗剂的调整后风险比为1.65(95%CI,1.22-2.23),均与带状疱疹风险增加相关。
- 与单用5-氨基水杨酸相比,单用TNF拮抗剂的调整后风险比为1.15(95%CI,0.96-1.38),未与带状疱疹风险增加相关。
- 所有年龄组和所有炎症性肠病药物亚组的带状疱疹发病率均显著高于年龄大于60岁的无炎症性肠病患者组。
关键数值与推荐
- 研究1:溃疡性结肠炎调整后风险比1.81(95%CI,1.56-2.11),克罗恩病调整后风险比1.56(95%CI,1.28-1.91),单用5-氨基水杨酸治疗的炎症性肠病调整后风险比1.72(95%CI,1.51-1.96),均与无炎症性肠病相比。
- 研究2:与单用5-氨基水杨酸相比,硫嘌呤类调整后风险比1.47(95%CI,1.31-1.65),硫嘌呤联合TNF拮抗剂调整后风险比1.65(95%CI,1.22-2.23),单用TNF拮抗剂调整后风险比1.15(95%CI,0.96-1.38)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) might be at increased risk for herpes zoster infection. We sought to quantify the risk of herpes zoster in patients with IBD and evaluate the effects of IBD and IBD medications on the risk of herpes zoster. METHODS: We conducted 2 retrospective studies of populations of Veterans, from January 2000 through June 2016. In study 1, we compared the incidence of herpes zoster among patients with IBD receiving 5-ASA alone vs matched patients without IBD. In study 2, we compared the incidence of herpes zoster among patients with IBD treated with only 5-ASA, with thiopurines, with antagonists of tumor necrosis factor (TNF), with a combination of thiopurines and TNF antagonists, and with vedolizumab. We used multivariable Cox regression to estimate the hazard ratios and 95% CIs for herpes zoster associated with IBD in study 1 and with different treatments in study 2. We also estimated the incidence rate of herpes zoster based on age and IBD medication subgroups. RESULTS: Compared to no IBD, ulcerative colitis (UC) and Crohn's disease (CD) were each associated with significantly increased risk of herpes zoster infection. In multivariable Cox regression (compared to no IBD), UC, CD, or IBD treated with 5-ASA treatment alone was associated with significantly increased risk of herpes zoster, with adjusted HRs (AHR) of 1.81 for UC (95% CI, 1.56-2.11), 1.56 for CD (95% CI, 1.28-1.91), and 1.72 for treated IBD (95% CI, 1.51-1.96). In multivariable Cox regression analysis, compared to exposure to 5-ASA alone, exposure to thiopurines (AHR, 1.47; 95% CI, 1.31-1.65) or a combination of thiopurines and TNF antagonists (AHR, 1.65; 95% CI, 1.22-2.23) was associated with increased risk of herpes zoster. However, exposure to TNF antagonists alone (AHR, 1.15; 95% CI, 0.96-1.38) was not associated with increased risk of herpes zoster. The incidence rates of herpes zoster in all age groups and all IBD medication subgroups were substantially higher than that in the oldest group of patients without IBD (older than 60 years). CONCLUSIONS: In 2 retrospective studies of Veteran populations, we associated IBD and treatment with thiopurines, alone or in combination with TNF antagonists, with increased risk of herpes zoster. With the approval of a new and potentially safer vaccine for herpes zoster, the effects of immunization of patients with IBD should be investigated.
引用
- Khan N, Patel D, Trivedi C, et al. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2018. PMID: 29309905. doi:10.1016/j.cgh.2017.12.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。